相关实验视频

Updated: May 21, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

丹杰类似冲击的特征预测了ST升高心肌梗塞相关心脏病性冲击的结果

Norman Mangner¹, Johannes Mierke¹, Dominik Baron¹

¹Department for Internal Medicine and Cardiology, Heart Centre Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.

ESC heart failure

|March 20, 2025

概括

符合DanGerShock试验标准的患者 (DGS类) 经过微轴流 (mAFP) 治疗的STEMI心脏性休克,其180天死亡率低于不符合标准的患者 (DGS类). 这突出了DGS资格作为STEMI-CS患者接受mAFP支持的生存预测指标.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
机械循环支持机械循环支持

背景情况:

丹格尔冲击 (DGS) 试验显示,微轴流量 (mAFP) 改善了STEMI-心血管冲击 (STEMI-CS) 的结果.
需要真实数据来评估DGS试验资格标准对使用mAFP治疗的更广泛的STEMI-CS群体的影响.

研究的目的:

评估DGS试验资格标准与180天死亡率之间的关联,在与mAFP治疗的真实世界STEMI-CS队列中.

主要方法:

分析了478名心脏性休克患者的前性单中心注册表,其中包括225名STEMI-CS患者.
如果患者符合特定的STEMI-CS标准 (乳酸盐≥2.5 mmol/L,LVEF<45%,没有重大并发症,特定的心脏骤停标准),则被归类为"DGS类"或"DGS不同",如果没有,则被归类为"DGS类".
主要结局是180天全因死亡率.

主要成果:

在225名STEMI-CS患者中,64人 (28.4%) 患有DGS类. 与DGS类似的患者年轻,并且接受mAFP的支持时间更长.
180天死亡率在DGS类似组 (62.5%) 与DGS不同组 (72.0%) (P=0.014) 相比显著较低.
类似于DGS的个人资料独立预测了较低的30天 (HR 0.48) 和180天 (HR 0.57) 死亡率.

结论:

在接受mAFP治疗的STEMI-CS患者中,类似DGS的概况与显著改善的生存率有关.
DGS资格标准可能有助于确定STEMI-CS患者在现实环境中最有可能从mAFP治疗中受益.

关键词:

心脏发生的冲击是心脏的冲击.丹格尔的冲击震惊了他们.机械循环支持机械循环支持微轴流量是一个微轴流量.ST-升高心肌梗塞的心脏病发作

更多相关视频

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Electrocardiogram

Electrocardiogram

An electrocardiogram (ECG or EKG) is a critical diagnostic tool that records the electrical signals produced by the heart during each heartbeat. This recording is achieved through electrodes placed strategically on the arms, legs, and chest. The electrocardiograph amplifies these signals and produces 12 distinct tracings, offering a comprehensive understanding of the heart's electrical activity.
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...